Granulocyte transfusions in the G-CSF era. Where do we stand?

Bone Marrow Transplantation

Volumn 34, Issue 10, 2004, Pages 839-846

  Robinson, Stephen P ^a   Marks, D I ^a  

^a BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

Author keywords

G CSF; Granulocyte transfusions; Neutropenia; Sepsis

Indexed keywords

DEXAMETHASONE; HLA ANTIGEN CLASS 1; PREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ARTHRALGIA; BLOOD SAMPLING; BONE PAIN; CATARACT; CELL COUNT; CHILL; DISEASE DURATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG ERUPTION; FATIGUE; FEVER; GRANULOCYTE TRANSFUSION; HEADACHE; HLA TYPING; HUMAN; IN VITRO STUDY; INSOMNIA; LUNG TOXICITY; MOOD DISORDER; MYALGIA; NAUSEA; NEUTROPENIA; NEUTROPHIL CHEMOTAXIS; PRIORITY JOURNAL; SEPSIS; SHORT SURVEY; SPLENOMEGALY;

GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTES; HUMANS; LEUKAPHERESIS; LEUKOCYTE TRANSFUSION; NEUTROPENIA; SEPSIS;

EID: 9444241031     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704630     Document Type: Short Survey

References (77)

1. Williamson E, Millar M, Steward C et al. Infections in adults undergoing unrelated donor bone marrow transplantation. Br J Haematol 1999; 104: 560-568.
2. Mitchell A, Derrington P, Tumer P et al. Gram-negative bacteraemia (GNB) after 428 unrelated donor bone marrow transplants (UD-BMT): risk factors, prophylaxis, therapy and outcome. Bone Marrow Transplant 2004; 33: 303-310.
3. Strumia MM. The effect of leukocyte cream injections in the treatment of neutropenias. Am J Med Sci 1934; 187: 527-544.
4. Brecher G, Wilbur KM, Kronkite EP. Transfusion of separated leukocytes into irradiated dogs with aplastic marrows. Proc Soc Exp Biol Med 1953; 84: 54-56.
5. Appelbaum FR, Bowles CA, Makuch RW et al. Granulocyte transfusion therapy of experimental Pseudomonas septicaemia: study of cell dose and collection technique. Blood 1978; 52: 323-331.
6. Strauss RG. Therapeutic granulocyte transfusions in 1993. Blood 1991; 81: 1675-1678.
7. Freireich EJ, Judson G, Levin RH. Separation and collection of leukocytes. Cancer Res 1965; 25: 1516-1520.
8. Yankee RA, Freireich EJ, Carbonne PP et al. Replacement therapy using normal and chronic myelogenous leukaemia leukocytes. Blood 1964; 24: 844-845.
9. Mishler JM. New dosage regimens for HES during intensive leukapheresis. Transfusion 1978; 18: 126.
10. McCredie KB, Freireich EJ, Hester JP et al. Increased granulocyte collection with the blood cell separator and the addition of etiocholanolone and hydroxyethyl starch. Transfusion 1974; 14 357-364.
11. Winton EF, Vogler WR. Development of a practical oral dexamethasone premedication schedule leading to improved granulocyte yields with the continuous-flow centrifugal blood cell separator. Blood 1978; 52: 249-253.
12. Buckner D, Graw RG, Eisel RJ et al. Leukapheresis by continuous flow centrifugation in patients with chronic myelocytic leukemia. Blood 1969; 33: 353-369.
13. Herzig RH, Herzig GP, Graw RG et al. Successful granulocyte transfusion therapy for gram-negative septicemia. N Engl J Med 1977; 296: 701-705.
14. Higby DJ, Yates JW, Henderson ES et al. Filtration lekapheresis for granulocyte transfusion therapy. Clinical and laboratory studies. N Engl J Med 1975; 292: 761-766.
15. Vogler WR, Winton EF. A controlled study of the efficacy of granulocyte transfusions in patients with neutropenia. Am J Med 1977; 63: 548-555.
16. Fortuny IE, Bloomfield CD, Hadlock DC et al. Granulocyte transfusion: a controlled study in patients with acute nonlymphocytic leukemia. Transfusion 1975; 15: 548-558.
17. Winston DJ, Ho WG, Gale WP. Therapeutic granulocyte transfusions for documented infections: a controlled trial in 95 infectious granulocytopenic episodes. Ann Intern Med 1982; 97 509-515.
18. Han P, Vincent PC. Problems with filtration-collected neutrophils. N Engl J Med 1976; 294: 729.
19. Wright DG, Robichaud KJ, Pizzo PA et al. Lethal pulmonary reactions associated with the combined use of amphotericin B and leukocyte transfusions. N Engl J Med 1981; 304: 1185-1189.
20. Wright DG, Kauffmann JC, Chusid MJ et al. Functional abnormalities of human neutrophils collected by continuous flow filtration leucopheresis. Blood 1975; 46: 901-911.
21. Winton EF, Vogler WR. Development of a practical oral dexamethasone premedication schedule leading to improved granulocyte yields with continuous-flow centrifugal blood cell separator. Blood 1978; 28: 249-253.
22. Liles WC, Huang JE, Llewellyn D et al. A comparative trial of granulocyte-colony-stimulating factor, separately and in combination, for the mobilisation of neutrophils in the peripheral blood of normal volunteers. Transfusion 1997; 37: 182-187.
23. Jendiroba DB, Lichtiger B, Anaissie E et al. Evaluation and comparison of three mobilisation methods for the collection of granulocytes. Transfusion 1998; 38: 722-728.
24. Demetri GD, Griffin JD. The role of granulocyte colony-stimulating factor and its receptor. Blood 1991; 78: 2791-2808.
25. Chatta GS, Price TH, Allen RC et al. Effects of in vivo recombinant methionyl human granulocyte colony-stimulating factor on the neutrophil response and peripheral blood colony-forming cells in healthy young and elderly adult volunteers. Blood 1994; 84: 2923-2929.
26. Bensinger WI, Price TH, Dale DC et al. The effects of daily recombinant granulocyte colony-stimulating factor administration on normal granulocyte donors undergoing leukapheresis. Blood 1993; 81: 1883-1888.
27. Liles WC, Rodger E, Dale DC. Combined administration of G-CSF and dexamethasone for the mobilisation of granulocytes in normal donors: optimisation of dosing. Transfusion 2000; 40: 642-644.
28. Caspar CB, Seger RA, Burger J et al. Effective stimulation of donors for granulocyte transfusions with methionyl granulocyte colony-stimulating factor. Blood 1993; 81: 2866-2871.
29. Dale DC, Liles WC, Llewellyn C et al. Neutrophil transfusions: kinetics and functions of neutrophils mobilized with granulocyte-colony-stimulating factor and dexamethasone. Transfusion 1998; 38: 713-721.
30. Leavey PJ, Thurman G, Ambruso DR. Functional characteristics of neutrophils collected and stored after administration of G-CSF. Transfusion 2000; 40: 414-419.
31. Lee JJ, Cheung IJ, Park MR et al. Clinical efficacy of granulocyte transfusion therapy in patients with neutropenia-related infections. Leukaemia 2001; 15: 203-207.
32. Adkins DR, Spitzer G, Johnston M et al. Transfusions of granulocyte-colony-stimulating factor-mobilized granulocyte components to allogeneic transplant recipients: analysis of kinetics and factors determining posttransfusion neutrophil and platelet counts. Transfusion 1997; 37: 737-748.
33. Adkins DR, Goodnough LT, Shenoy S et al. Effect of leukocyte compatibility on neutrophil increment after transfusion of granulocyte colony-stimulating factor-mobilized prophylactic granulocyte transfusions and on clinical outcomes after stem cell transplantation. Blood 2000; 95: 3602-3612.
34. Hubel K, Carter RA, Liles C et al. Granulocyte transfusion therapy for infections in candidates and recipients of HPC transplantation: a comparative analysis of feasibility and outcome for community vs related donors. Transfusion 2002; 42: 1414-1421.
35. Stroncek DF, Matthews CL, Follman D et al. Kinetics of G-CSF-induced granulocyte mobilisation in healthy subjects: effects of route of administration and addition of dexamethasone. Transfusion 2002; 42: 597-602.
36. Leitman SF, Yu M, Lekstrom J. Pair controlled study of granulocyte colony stimulating factor (G-CSF) for granulocytapheresis donors. Transfusion 1995; 35 (Suppl): 53S (abstract).
37. Glasser L, Fiederlein RL, Huestis DW. Liquid preservation of human neutrophils stored in synthetic media at 22°C: controlled observations on storage variables. Blood 1985; 66: 267.
38. American Association of Blood Banks. AABB Technical Manual 14th edn. American Association of Blood Banks: MD, USA, 2002.
39. Council of Europe. Council of Europe Guide to the Preparation, Use and Quality Assurance of Blood Components, 9th edn. Council of Europe Publishing: Strasbourg, France, 2003.
40. Hubel K, Dale DC, Rodger E et al. Preservation of function in granulocyte concentrates collected from donors stimulated with G-CSF/dexamethasone during storage at reduced temperature. Blood 2000; 96: 820a.
41. McCullough J, Clay M, Herr G et al. Effects of granulocyte-colony-stimulating factor on potential normal granulocyte donors. Transfusion 1999; 39: 1136-1140.
42. Ghodsi Z, Strauss RG. Cataracts in neutrophil donors stimulated with adrenal corticosteroids. Transfusion 2001; 41 1464-1468.
43. Stroncek DF, Clay ME, Herr G et al. Blood counts in healthy donors 1 year after the collection of granulocyte colony-stimulating factor-mobilized progenitor cells and the results of a second mobilization and collection. Transfusion 1997; 37: 304-308.
44. Cavallaro AM, Lilleby K, Majolino I et al. Three to six year follow-up of normal donors who received recombinant human granulocyte colony-stimulating factor. Bone Marrow Transplant 2000; 25: 85-89.
45. Price TH, Bowden RA, Boeckh M et al. Phase I/II trial of neutrophil transfusions from donors stimulated with G-CSF and dexamethasone for the treatment of patients with infections in hematopoietic stem cell transplantation. Blood 2000; 95: 3302-3309.
46. Narvios A, Pena E, Xiang-Yang H et al. Cytomegalovirus infections in cancer patients receiving granulocyte transfusions. Blood 2002; 99: 390-391 (Letter).
47. Vij R, DiPersio JF, Venkatraman P et al. Donor CMV serostatus has no impact on CMV viremia or disease when prophylactic granulocyte transfusions are given following allogeneic peripheral blood stem cell transplantation. Blood 2003; 101: 2067-2069.
48. Nichols GW, Price T, Boeckh M. Cytomegalovirus infections in cancer patients receiving granulocyte transfusions. Blood 2002; 99: 2483-3484 (Letter).
49. Nichols GW, Price T, Boeckh M. Donor serostatus and CMV infection and disease among recipients of prophylactic granulocyte transfusions. Blood 2003; 101: 5091-5092 (Letter).
50. Peters C, Minkov M, Matthes-Martin S et al. Leucocyte transfusions from rhG-CSF or prednisolone stimulated donors for treatment of severe infections in immunocompromised neutropenic patients. Br J Haematol 1999; 106: 689-696.
51. Illerhaus G, Wirth K, Dwenger A et al. Treatment and prophylaxis of severe infections in neutropenic infections by granulocyte transfusions. Am Hematol 2002; 81: 273-281.
52. Rutella S, Pierelli L, Sica S et al. Efficacy of granulocyte transfusions for neutropenia-related infections: retrospective analysis of predictive factors. Cytotherapy 2003; 5: 19-30.
53. Cesaro S, Chinello P, De Silvestro G et al. Granulocyte transfusions from G-CSF-stimulated donors for the treatment of severe infections in neutropenic pediatric patients with onco-hematological diseases. Support Care Cancer 2003; 11: 101-106.
54. Grigull L, Schrauder A, Schmitt-Thomssen A et al. Efficacy and safety of G-CSF mobilised granulocyte transfusions in four neutropenic children with sepsis and invasive fungal infections. Infection 2002; 30: 267-271.
55. Adkins D, Goodnough LT, Moellering J et al. Reduction in antibiotic utilization and if febrile days by transfusion of G-CSF mobilised prophylactic granulocyte components: a randomised study. Blood 1999; 94: 590a.
56. Blum W, Hallem C, Vij R et al. Improved survival in allogeneic peripheral blood stem cell (PBSC) transplant patients who received prophylactic granulocyte transfusions from HLA-matched donors: long term follow-up. Blood 2001; 98: 58a.
57. Kerr PJ, Liakopolou E, Brown J et al. The use of stimulated granulocyte transfusions to prevent recurrence of past severe infections after allogeneic stem cell transplantation. Br J Haematol 2003; 123: 114-118.
58. Goldstein IM, Eyre HJ, Terasaki PI et al. Leukocyte transfusions: role of leukocyte alloantibodies in determining transfusion response. Transfusions 1971; 11: 19-24.
59. Graw RG, Eyre HJ, Goldstein IM et al. Histocompatibility testing for leucocyte transfusion. Lancet 1970; 1: 77-78.
60. Westrick MA, Debelak-Fehir KM, Epstein RB. The effect of prior whole blood transfusion on subsequent support in leukopenic dogs. Transfusion 1977; 17: 611-614.
61. McCullough J, Weiblen BJ, Clay ME et al. Effect of leukocyte antibodies on the fate in vivo of indium-111-labelled granulocytes. Blood 1981; 58: 164-170.
62. Stroncek DF, Leonard K, Eiber HL et al. Alloimmunisation after granulocyte transfusions. Transfusion 1996; 36: 1009-1015.
63. Dutcher JP, Schiffer CA, Johnston GS et al. Alloimmunisation prevents the migration of transfused indium-111-labelled granulocytes to sites of infection. Blood 1983; 62: 354-360.
64. Appelbaum FR, Trapani RJ, Graw Jr RG. Consequences of prior alloimmunisation during granulocyte transfusion. Transfusion 1977; 17: 460-464.
65. Boggs DR. Transfusion of neutrophits as prevention or treatment of infection in patients with neutropenia. N Engl J Med 1974; 290: 1055-1062.
66. Watanabe C, Yajima S, Taguchi T et al. Successful unrelated bone marrow trasplantation for a patient with chronic granulomatous disease and associated resistant pneumonitis and Aspergillus osteomyelitis. Bone Marrow Transplant 2001; 28: 83-87.
67. Bielorai B, Toren A, Wolach B et al. Successful treatment of invasive aspergillosis in chronic granulomatous disease by granulocyte transfusions followed by peripheral blood stem cell transplantation. Bone Marrow Transplant 2000; 26: 1025-1028.
68. Dale DC. Renewed interest in granulocyte transfusion therapy. Br J Haematol 1997; 98: 497-501.
69. Winston DJ, Ho WG, Young LS et al. Prophylactic granulocyte transfusions during human bone marrow transplantation. Am J Med 1980; 68: 893-897.
70. Strauss RG, Connett JE, Gale RP et al. A controlled trial of prophylactic granulocyte transfusions during initial induction chemotherapy for acute myelogenous leukaemia. N Engl J Med 1981; 305: 597-603.
71. Winston DJ, Ho WG, Gale RP. Prophylactic granulocyte transfusions during chemotherapy for acute nonlymphocytic leukemia. Ann Int Med 1981; 94: 616-622.
72. Ford JM, Cullen MH, Roberts MM et al. Prophylactic granulocyte transfusions: results of a randomised controlled trial in patients with acute myelogenous leukemia. Transfusion 1982; 22 311-316.
73. Vamvakas EC, Pineda AA. Determinants of the efficacy of prophylactic granulocyte transfusions: a meta-analysis. J Clin Apheresis 1997; 12: 74-81.
74. Herman S, Klein SA, Jacobi V et al. Older patients with high-risk fungal infections can be successfully allografted using nonmyeloablative conditioning in combination with intensified supportive care regimens. Br J Haematol 2000; 113: 446-454.
75. Ascioglu S, Rex JH. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7-14.
76. Sachs UJ, Bux J. TRALI after the transfusion of cross-match-positive granulocytes. Transfusion 2003; 43: 1683-1686.
77. Schiffer CA, Aisner J, Daly PA et al. Alloimmunisation following prophylactic granulocyte transfusion. Blood 1979; 54 766-774.